Chlorcyclizine | hsa00040 | Pentose and glucuronate interconversions | 4.00E-02 | 1 | P15121 | AKR1B1 | More | |
Chlorcyclizine | hsa00190 | Oxidative phosphorylation | 5.61E-05 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | |
Chlorcyclizine | hsa00220 | Arginine biosynthesis | 1.97E-02 | 2 | P15104, P49448 | GLUL, GLUD2 | More | |
Chlorcyclizine | hsa00230 | Purine metabolism | 1.81E-02 | 2 | P20839, Q02153 | IMPDH1, GUCY1B3 | More | |
Chlorcyclizine | hsa00250 | Alanine, aspartate and glutamate metabolism | 1.97E-02 | 2 | P49448, P15104 | GLUD2, GLUL | More | |
Chlorcyclizine | hsa00260 | Glycine, serine and threonine metabolism | 1.99E-02 | 1 | P22557 | ALAS2 | More | |
Chlorcyclizine | hsa00565 | Ether lipid metabolism | 3.94E-02 | 1 | Q8N661 | TMEM86B | More | |
Chlorcyclizine | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | |
Chlorcyclizine | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | |
Chlorcyclizine | hsa00760 | Nicotinate and nicotinamide metabolism | 3.52E-02 | 1 | P21589 | NT5E | More | |
Chlorcyclizine | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
Chlorcyclizine | hsa00790 | Folate biosynthesis | 2.02E-02 | 1 | P15121 | AKR1B1 | More | |
Chlorcyclizine | hsa00910 | Nitrogen metabolism | 1.97E-02 | 2 | P15104, P49448 | GLUL, GLUD2 | More | |
Chlorcyclizine | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 6.38E-04 | 3 | P78417, P09211, P11712 | GSTO1, GSTP1, CYP2C9 | More | |
Chlorcyclizine | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | |
Chlorcyclizine | hsa00983 | Drug metabolism - other enzymes | 3.50E-02 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | |
Chlorcyclizine | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P08069 | IGF1R | More | |
Chlorcyclizine | hsa01522 | Endocrine resistance | 2.16E-02 | 1 | P08069 | IGF1R | More | |
Chlorcyclizine | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | |
Chlorcyclizine | hsa03010 | Ribosome | 2.25E-04 | 5 | P40429, Q07020, P27635, P05386, P62249 | RPL13A, RPL18, RPL10, RPLP1, RPS16 | More | |
Chlorcyclizine | hsa03013 | RNA transport | 3.98E-02 | 9 | P52298, Q09161, O14893, Q7Z3B4, P35658, Q14152, O75822, P78345, Q9Y6A5 | NCBP2, NCBP1, GEMIN2, NUP54, NUP214, EIF3A, EIF3J, RPP38, TACC3 | More | |
Chlorcyclizine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | |
Chlorcyclizine | hsa04010 | MAPK signaling pathway | 4.15E-02 | 1 | P08069 | IGF1R | More | |
Chlorcyclizine | hsa04014 | Ras signaling pathway | 3.65E-02 | 1 | P08069 | IGF1R | More | |
Chlorcyclizine | hsa04015 | Rap1 signaling pathway | 2.99E-02 | 1 | P08069 | IGF1R | More | |
Chlorcyclizine | hsa04060 | Cytokine-cytokine receptor interaction | 4.71E-02 | 2 | P78552, O75509 | IL13RA1, TNFRSF21 | More | |
Chlorcyclizine | hsa04064 | NF-kappa B signaling pathway | 1.60E-02 | 8 | P10415, O00463, Q04759, Q9UDY8, Q16548, Q13315, P24522, P09341 | BCL2, TRAF5, PRKCQ, MALT1, BCL2A1, ATM, GADD45A, CXCL1 | More | |
Chlorcyclizine | hsa04066 | HIF-1 signaling pathway | 2.16E-02 | 1 | P08069 | IGF1R | More | |
Chlorcyclizine | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | |
Chlorcyclizine | hsa04071 | Sphingolipid signaling pathway | 3.76E-03 | 7 | P21453, Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415 | S1PR1, EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2 | More | |
Chlorcyclizine | hsa04072 | Phospholipase D signaling pathway | 9.70E-03 | 2 | Q92529, Q14344 | SHC3, GNA13 | More | |
Chlorcyclizine | hsa04080 | Neuroactive ligand-receptor interaction | 3.22E-02 | 7 | P08311, Q15722, P21453, Q9H228, O00398, P21730, Q16581 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, C5AR1, C3AR1 | More | |
Chlorcyclizine | hsa04114 | Oocyte meiosis | 2.99E-02 | 1 | P08069 | IGF1R | More | |
Chlorcyclizine | hsa04115 | p53 signaling pathway | 3.98E-02 | 5 | P24522, Q13315, Q53FA7, O95067, P10415 | GADD45A, ATM, TP53I3, CCNB2, BCL2 | More | |
Chlorcyclizine | hsa04120 | Ubiquitin mediated proteolysis | 2.51E-03 | 6 | Q14145, Q13042, P62837, Q15751, O95071, P0CG47 | KEAP1, CDC16, UBE2D2, HERC1, UBR5, UBB | More | |
Chlorcyclizine | hsa04137 | Mitophagy - animal | 9.52E-03 | 2 | Q07817, P0CG47 | BCL2L1, UBB | More | |
Chlorcyclizine | hsa04140 | Autophagy - animal | 2.82E-02 | 1 | P08069 | IGF1R | More | |
Chlorcyclizine | hsa04145 | Phagosome | 1.66E-03 | 9 | Q15080, P14598, Q13509, P68371, Q13488, P05164, O60603, P35443, P13765 | NCF4, NCF1, TUBB3, TUBB2C, TCIRG1, MPO, TLR2, THBS4, HLA-DOB | More | |
Chlorcyclizine | hsa04150 | mTOR signaling pathway | 2.32E-02 | 1 | P08069 | IGF1R | More | |
Chlorcyclizine | hsa04151 | PI3K-Akt signaling pathway | 3.96E-02 | 8 | P43657, P09603, Q9GZP0, P63218, P50151, P13612, O15335, Q13751 | P2RY5, CSF1, PDGFD, GNG5, GNG10, ITGA4, CHAD, LAMB3 | More | |
Chlorcyclizine | hsa04152 | AMPK signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | |
Chlorcyclizine | hsa04210 | Apoptosis | 3.77E-02 | 8 | Q13315, P10415, O76075, P24522, Q16548, P43234, P18848, Q14643 | ATM, BCL2, DFFB, GADD45A, BCL2A1, CTSO, ATF4, ITPR1 | More | |
Chlorcyclizine | hsa04211 | Longevity regulating pathway | 2.16E-02 | 1 | P08069 | IGF1R | More | |
Chlorcyclizine | hsa04213 | Longevity regulating pathway - multiple species | 1.66E-02 | 1 | P08069 | IGF1R | More | |
Chlorcyclizine | hsa04217 | Necroptosis | 2.24E-04 | 12 | P01375, P01568, P48023, Q13489, P42224, Q14765, P08238, Q6FI13, Q99878, Q93077, O43633, Q08752 | TNF, IFNA21, FASLG, BIRC3, STAT1, STAT4, HSP90AB1, H2AC18; H2AC19, H2AC14, HIST1H2AC, CHMP2A, PPID | More | |
Chlorcyclizine | hsa04340 | Hedgehog signaling pathway | 3.46E-02 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | |
Chlorcyclizine | hsa04510 | Focal adhesion | 3.48E-02 | 1 | P08069 | IGF1R | More | |
Chlorcyclizine | hsa04512 | ECM-receptor interaction | 4.41E-02 | 3 | Q13751, P13612, O15335 | LAMB3, ITGA4, CHAD | More | |
Chlorcyclizine | hsa04520 | Adherens junction | 8.29E-03 | 1 | P08069 | IGF1R | More | |
Chlorcyclizine | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | |
Chlorcyclizine | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.99E-02 | 1 | P08069 | IGF1R | More | |
Chlorcyclizine | hsa04612 | Antigen processing and presentation | 2.26E-03 | 8 | P13765, P48382, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | |
Chlorcyclizine | hsa04613 | Neutrophil extracellular trap formation | 6.94E-04 | 18 | O60603, P05164, P08246, Q9UM07, P04908, Q6FI13, Q93077, P62807, O60814, P68431, Q15080, P20160, P08311, O75015, P21730, P21462, O43315, Q16539 | TLR2, MPO, ELA2, PADI4, H2AC4; H2AC8, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF4, AZU1, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | |
Chlorcyclizine | hsa04621 | NOD-like receptor signaling pathway | 2.62E-02 | 11 | Q16539, Q14643, P10599, Q9H1Y0, P43490, O00463, P10415, Q05823, P01375, P09341, P12838 | MAPK14, ITPR1, TXN, ATG5, PBEF1, TRAF5, BCL2, RNASEL, TNF, CXCL1, DEFA4 | More | |
Chlorcyclizine | hsa04623 | Cytosolic DNA-sensing pathway | 3.15E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | |
Chlorcyclizine | hsa04657 | IL-17 signaling pathway | 3.91E-02 | 7 | O00463, Q16539, P49841, P09341, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF | More | |
Chlorcyclizine | hsa04658 | Th1 and Th2 cell differentiation | 1.12E-02 | 8 | Q04759, P20963, P09693, Q16539, Q14765, P23771, Q9UL17, P13765 | PRKCQ, CD247, CD3G, MAPK14, STAT4, GATA3, TBX21, HLA-DOB | More | |
Chlorcyclizine | hsa04660 | T cell receptor signaling pathway | 3.76E-03 | 11 | P01375, Q9UDY8, Q04759, O95267, Q08881, P20963, P09693, P01732, Q13191, Q16539, P49841 | TNF, MALT1, PRKCQ, RASGRP1, ITK, CD247, CD3G, CD8A, CBLB, MAPK14, GSK3B | More | |
Chlorcyclizine | hsa04666 | Fc gamma R-mediated phagocytosis | 2.42E-02 | 5 | P23528, P06396, O14494, P14598, P17252 | CFL1, GSN, PLPP1, NCF1, PRKCA | More | |
Chlorcyclizine | hsa04672 | Intestinal immune network for IgA production | 1.62E-02 | 3 | P29965, P10747, P13765 | CD40LG, CD28, HLA-DOB | More | |
Chlorcyclizine | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | |
Chlorcyclizine | hsa04721 | Synaptic vesicle cycle | 3.15E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | |
Chlorcyclizine | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | |
Chlorcyclizine | hsa04724 | Glutamatergic synapse | 9.51E-03 | 4 | O15399, P63218, P50151, P15104 | GRIN2D, GNG5, GNG10, GLUL | More | |
Chlorcyclizine | hsa04725 | Cholinergic synapse | 4.83E-02 | 4 | P22694, Q14643, P18848, P10415 | PRKACB, ITPR1, ATF4, BCL2 | More | |
Chlorcyclizine | hsa04727 | GABAergic synapse | 2.33E-02 | 3 | P63218, P50151, P15104 | GNG5, GNG10, GLUL | More | |
Chlorcyclizine | hsa04730 | Long-term depression | 1.26E-03 | 3 | Q14344, P08069, P07948 | GNA13, IGF1R, LYN | More | |
Chlorcyclizine | hsa04744 | Phototransduction | 2.80E-02 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | |
Chlorcyclizine | hsa04913 | Ovarian steroidogenesis | 1.16E-02 | 1 | P08069 | IGF1R | More | |
Chlorcyclizine | hsa04914 | Progesterone-mediated oocyte maturation | 2.16E-02 | 1 | P08069 | IGF1R | More | |
Chlorcyclizine | hsa04915 | Estrogen signaling pathway | 2.96E-02 | 5 | P14780, P22694, P18848, Q14643, P10415 | MMP9, PRKACB, ATF4, ITPR1, BCL2 | More | |
Chlorcyclizine | hsa04916 | Melanogenesis | 4.80E-02 | 4 | P0DP23, Q9UJU2, P17252, P04628 | CALM1, LEF1, PRKCA, WNT1 | More | |
Chlorcyclizine | hsa04918 | Thyroid hormone synthesis | 3.50E-02 | 3 | P22694, P18848, Q14643 | PRKACB, ATF4, ITPR1 | More | |
Chlorcyclizine | hsa04927 | Cortisol synthesis and secretion | 8.60E-03 | 3 | Q14643, P18848, P22694 | ITPR1, ATF4, PRKACB | More | |
Chlorcyclizine | hsa04928 | Parathyroid hormone synthesis, secretion and action | 2.13E-02 | 5 | Q14643, P22694, P23771, P18848, P10415 | ITPR1, PRKACB, GATA3, ATF4, BCL2 | More | |
Chlorcyclizine | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | |
Chlorcyclizine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Chlorcyclizine | hsa04960 | Aldosterone-regulated sodium reabsorption | 4.38E-02 | 1 | P48048 | KCNJ1 | More | |
Chlorcyclizine | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | |
Chlorcyclizine | hsa05010 | Alzheimer disease | 4.39E-02 | 6 | O15399, Q9NZJ5, Q13564, Q71U36, P09603, P21796 | GRIN2D, EIF2AK3, APPBP1, TUBA1A, CSF1, VDAC1 | More | |
Chlorcyclizine | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | |
Chlorcyclizine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | |
Chlorcyclizine | hsa05032 | Morphine addiction | 1.34E-02 | 4 | P63218, P50151, Q07343, P43250 | GNG5, GNG10, PDE4B, GRK6 | More | |
Chlorcyclizine | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
Chlorcyclizine | hsa05132 | Salmonella infection | 2.93E-02 | 10 | P51617, Q9UJU2, Q13489, P10415, O75369, O60603, Q9BQS8, Q13561, Q13509, P68371 | IRAK1, LEF1, BIRC3, BCL2, FLNB, TLR2, FYCO1, DCTN2, TUBB3, TUBB2C | More | |
Chlorcyclizine | hsa05140 | Leishmaniasis | 9.39E-04 | 11 | P13612, O75015, P14598, P42224, P13765, O60603, P25963, P01375, P29350, Q16539, Q15080 | ITGA4, FCGR3B, NCF1, STAT1, HLA-DOB, TLR2, NFKBIA, TNF, PTPN6, MAPK14, NCF4 | More | |
Chlorcyclizine | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | |
Chlorcyclizine | hsa05146 | Amoebiasis | 3.91E-02 | 7 | P09341, P27930, P01375, O60603, P05089, P22694, P08311 | CXCL1, IL1R2, TNF, TLR2, ARG1, PRKACB, CTSG | More | |
Chlorcyclizine | hsa05152 | Tuberculosis | 5.68E-03 | 9 | Q13488, P0DP23, P48382, O60603, P10415, P13765, P01568, Q9UDY8, P51617 | TCIRG1, CALM1, RFX5, TLR2, BCL2, HLA-DOB, IFNA21, MALT1, IRAK1 | More | |
Chlorcyclizine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | |
Chlorcyclizine | hsa05168 | Herpes simplex virus 1 infection | 3.38E-03 | 12 | P25963, P01568, Q05823, P42224, Q07955, Q13243, Q13489, Q13398, Q9HCX3, P52738, O75820, Q9UDV6 | NFKBIA, IFNA21, RNASEL, STAT1, SFRS1, SFRS5, BIRC3, ZNF211, ZNF304, ZNF140, ZNF189, ZNF212 | More | |
Chlorcyclizine | hsa05170 | Human immunodeficiency virus 1 infection | 5.94E-03 | 12 | P62873, P0DP23, P17252, O00463, Q14643, P01568, P51617, O60603, P23528, P10415, Q93034, Q9Y6Q5 | GNB1, CALM1, PRKCA, TRAF5, ITPR1, IFNA21, IRAK1, TLR2, CFL1, BCL2, CUL5, AP1M2 | More | |
Chlorcyclizine | hsa05171 | Coronavirus disease - COVID-19 | 3.87E-04 | 5 | P62249, P40429, P27635, Q07020, P05386 | RPS16, RPL13A, RPL10, RPL18, RPLP1 | More | |
Chlorcyclizine | hsa05202 | Transcriptional misregulation in cancer | 1.39E-05 | 20 | Q12778, Q15532, Q13315, P14780, P27930, P14923, Q15744, Q16548, Q13489, Q13077, O15550, P08069, P35226, P05164, P12838, P08246, Q9C0K0, P41182, P12980, P24522 | FOXO1, SS18, ATM, MMP9, IL1R2, JUP, CEBPE, BCL2A1, BIRC3, TRAF1, UTX, IGF1R, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, LYL1, GADD45A | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P10415 | BCL2 | Apoptosis regulator Bcl-2 | Q12778 | FOXO1 | Forkhead box protein O1 | 0.794 | P05164 | MPO | Myeloperoxidase | Q15532 | SS18 | Protein SSXT | -0.719 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | Q15532 | SS18 | Protein SSXT | 0.877 | P05164 | MPO | Myeloperoxidase | Q13315 | ATM | Serine-protein kinase ATM | -0.725 | P05164 | MPO | Myeloperoxidase | P14780 | MMP9 | Matrix metalloproteinase-9 | 0.812 | P14780 | MMP9 | Matrix metalloproteinase-9 | P14780 | MMP9 | Matrix metalloproteinase-9 | 1 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | P14780 | MMP9 | Matrix metalloproteinase-9 | -0.765 | P14780 | MMP9 | Matrix metalloproteinase-9 | P27930 | IL1R2 | Interleukin-1 receptor type 2 | 0.851 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | P14923 | JUP | Junction plakoglobin | 0.861 | P05164 | MPO | Myeloperoxidase | Q15744 | CEBPE | CCAAT/enhancer-binding protein epsilon | 0.799 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q15744 | CEBPE | CCAAT/enhancer-binding protein epsilon | 0.7 | P05164 | MPO | Myeloperoxidase | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.782 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.921 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | -0.746 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | 0.848 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.758 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | 0.816 | P05164 | MPO | Myeloperoxidase | O15550 | UTX | Lysine-specific demethylase 6A | 0.763 | P08069 | IGF1R | Insulin-like growth factor 1 receptor | P08069 | IGF1R | Insulin-like growth factor 1 receptor | 1 | P14780 | MMP9 | Matrix metalloproteinase-9 | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.89 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | P35226 | BMI1 | Polycomb complex protein BMI-1 | 0.78 | P14780 | MMP9 | Matrix metalloproteinase-9 | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.89 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | P35226 | BMI1 | Polycomb complex protein BMI-1 | 0.78 | P05164 | MPO | Myeloperoxidase | P05164 | MPO | Myeloperoxidase | 1 | P14780 | MMP9 | Matrix metalloproteinase-9 | P05164 | MPO | Myeloperoxidase | 0.812 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | P05164 | MPO | Myeloperoxidase | -0.81 | P05164 | MPO | Myeloperoxidase | P12838 | DEFA4 | Neutrophil defensin 4 | 0.733 | P14780 | MMP9 | Matrix metalloproteinase-9 | P12838 | DEFA4 | Neutrophil defensin 4 | 0.858 | P05164 | MPO | Myeloperoxidase | P08246 | ELA2 | Neutrophil elastase | 0.903 | P14780 | MMP9 | Matrix metalloproteinase-9 | P08246 | ELA2 | Neutrophil elastase | 0.859 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | P08246 | ELA2 | Neutrophil elastase | -0.942 | P05164 | MPO | Myeloperoxidase | Q9C0K0 | BCL11B | B-cell lymphoma/leukemia 11B | -0.854 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q9C0K0 | BCL11B | B-cell lymphoma/leukemia 11B | -0.752 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | Q9C0K0 | BCL11B | B-cell lymphoma/leukemia 11B | 0.766 | P14780 | MMP9 | Matrix metalloproteinase-9 | P41182 | BCL6 | B-cell lymphoma 6 protein | 0.812 | P14780 | MMP9 | Matrix metalloproteinase-9 | P12980 | LYL1 | Protein lyl-1 | 0.716 | P05164 | MPO | Myeloperoxidase | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.812 | P14780 | MMP9 | Matrix metalloproteinase-9 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.765 |
|
Chlorcyclizine | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | |
Chlorcyclizine | hsa05204 | Chemical carcinogenesis | 1.09E-03 | 3 | P09211, P78417, P11712 | GSTP1, GSTO1, CYP2C9 | More | |
Chlorcyclizine | hsa05205 | Proteoglycans in cancer | 4.93E-03 | 11 | Q13009, Q12955, Q14643, O75369, P14780, P17252, O60603, P08069, P04628, Q13635, P08962 | TIAM1, ANK3, ITPR1, FLNB, MMP9, PRKCA, TLR2, IGF1R, WNT1, PTCH1, CD63 | More | |
Chlorcyclizine | hsa05214 | Glioma | 9.95E-03 | 1 | P08069 | IGF1R | More | |
Chlorcyclizine | hsa05215 | Prostate cancer | 1.33E-02 | 1 | P08069 | IGF1R | More | |
Chlorcyclizine | hsa05218 | Melanoma | 6.63E-03 | 1 | P08069 | IGF1R | More | |
Chlorcyclizine | hsa05224 | Breast cancer | 1.49E-02 | 1 | P08069 | IGF1R | More | |
Chlorcyclizine | hsa05225 | Hepatocellular carcinoma | 6.30E-04 | 3 | Q92529, P08069, P51531 | SHC3, IGF1R, SMARCA2 | More | |
Chlorcyclizine | hsa05310 | Asthma | 2.81E-02 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | |
Chlorcyclizine | hsa05320 | Autoimmune thyroid disease | 8.64E-03 | 4 | P13765, P29965, P01568, P10747 | HLA-DOB, CD40LG, IFNA21, CD28 | More | |
Chlorcyclizine | hsa05321 | Inflammatory bowel disease | 2.00E-04 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P23771, Q9HBE5 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3, IL21R | More | |
Chlorcyclizine | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
Chlorcyclizine | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Chlorcyclizine | hsa05332 | Graft-versus-host disease | 9.76E-05 | 6 | P13765, P48023, P10747, P01375, P26715, Q13241 | HLA-DOB, FASLG, CD28, TNF, KLRC1, KLRD1 | More | |
Chlorcyclizine | hsa05415 | Diabetic cardiomyopathy | 4.54E-04 | 8 | P17252, P14598, Q15080, Q16718, O14521, Q16539, P49841, P04406 | PRKCA, NCF1, NCF4, NDUFA5, SDHD, MAPK14, GSK3B, GAPDH | More | |